The company plans to raise NIS 30 million.
IceCure Medical published a draft prospectus today for an offering on the Tel Aviv Stock Exchange. The company intends to raise some NIS 30 million. This draft is the first published by a biomed company after five offerings by such companies were cancelled in the previous quarter.
The company's first product is for the removal of benign growths from the breast. The product obtained US Food and Drug Administration approval last year, and it is also approved for sale in Europe.
Among IceCure's shareholders are Giza (33%), Docor (16%), and Ofer Hi-Tech (11%.
Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011